Clinical Trials Browser

Completed × cabozantinib × Breast × Clear all

Breast Neoplasms, Neoplasm Metastasis

NCT00940225 2024-04-25

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Phase 1 Completed

210 enrolled

BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

NCT03316586 2021-12-28

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

Phase 2 Completed

18 enrolled 16 charts

Breast

Breast Neoplasms

NCT02260531 2021-05-20

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

Phase 2 Completed

36 enrolled 19 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01738438 2016-12-06

Cabozantinib for Metastatic Triple Negative BrCa

Phase 2 Completed

35 enrolled 7 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

Clinical Trials

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

Cabozantinib for Metastatic Triple Negative BrCa